Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) Other Operating Expenses (2020 - 2025)

Rapid Micro Biosystems' Other Operating Expenses history spans 6 years, with the latest figure at $14.9 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 46.12% to $14.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.6 million, a 7.71% increase, with the full-year FY2025 number at $44.6 million, up 7.71% from a year prior.
  • Other Operating Expenses hit $14.9 million in Q4 2025 for Rapid Micro Biosystems, up from $10.0 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for RPID hit a ceiling of $14.9 million in Q4 2025 and a floor of $8.6 million in Q2 2022.
  • Historically, Other Operating Expenses has averaged $10.5 million across 5 years, with a median of $10.3 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: surged 103.58% in 2021 and later decreased 22.35% in 2022.
  • Tracing RPID's Other Operating Expenses over 5 years: stood at $11.1 million in 2021, then decreased by 0.45% to $11.1 million in 2022, then fell by 12.88% to $9.7 million in 2023, then rose by 5.68% to $10.2 million in 2024, then soared by 46.12% to $14.9 million in 2025.
  • Business Quant data shows Other Operating Expenses for RPID at $14.9 million in Q4 2025, $10.0 million in Q3 2025, and $10.1 million in Q2 2025.